FDA proposes removing obesity and diabetes drug ingredients from compounding substances list

The U.S. Food and Drug Administration has issued a proposal to remove the active ingredients of widely used obesity and diabetes medicines from the list of substances that can be compounded. The change would prevent pharmacies from creating custom versions of these drugs using compounding techniques.

The agency said the move is intended to protect patients, citing concerns that compounded versions may not meet the same safety and efficacy standards as the approved products. If adopted, manufacturers of the listed drugs would no longer be able to rely on compounding as an alternative distribution channel.

The announcement appeared in a STAT Pharmalot newsletter that also noted an AstraZeneca setback, though the brief did not provide further details.